All relevant data are within the paper and its Supporting Information files. We have provided raw data in submission.

Introduction {#sec009}
============

The worldwide prevalence of pseudoexfoliation (PXF) and pseudoexfoliation glaucoma (PXG) varies widely ranging from 0--80% with maximal prevalence in Scandinavian countries. \[[@pone.0233268.ref001]--[@pone.0233268.ref004]\] Its unique clinical feature of flaky white pseudoexfoliative material (XFM) on different ocular structures combined with progressive neurodegeneration and systemic associations mandates its recognition as a unique identity among all forms of glaucoma. \[[@pone.0233268.ref005]\] Recognition of this entity is not only important to identify possible surgery related devastating complications in routine cataract surgery but also aids in identifying eyes at risk for developing long term irreversible ocular hypertension or glaucoma related blindness. \[[@pone.0233268.ref003],[@pone.0233268.ref005]--[@pone.0233268.ref007]\] Early recognition and prognostication of this entity remains the only means for preventing onset of glaucoma since the pathogenesis of the irreversible glaucoma still remains a mystery. \[[@pone.0233268.ref001]\] Details on the vast clinical spectrum of the disease and the frequency of blindness due to PXF at presentation are scarce in literature with most studies focussing on genetic aetiology, pathogenesis or prevalence of the disease in a particular geographical location or country. \[[@pone.0233268.ref005],[@pone.0233268.ref008],[@pone.0233268.ref009],[@pone.0233268.ref010]\]

The long term progression from glaucoma suspect to ocular hypertension or established glaucoma is well characterised in randomised controlled trials for primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG). \[[@pone.0233268.ref011],[@pone.0233268.ref012]\] Yet parallel epidemiological studies on pseudoexfoliation focus mostly on prevalence rates in specific geographical locations with minimal or no reference to its different stages or blindness rates in different disease stages like PXF only, ocular hypertension (OHT) and pseudoexfoliation glaucoma (PXG). \[[@pone.0233268.ref008]--[@pone.0233268.ref010]\] This disease is very well characterised clinically with detailed description of the complications associated with cataract surgery performed in eyes with PXF. \[[@pone.0233268.ref001],[@pone.0233268.ref005],[@pone.0233268.ref006]\] Also known is the faster rate of visual field progression in eyes with PXF which is partly explained by refractoriness to conventional therapy in these eyes. Very few studies have described the extent of visual impairment of the disease stages at baseline which may possibly give a clue to the actual disease burden of the disease across its varied stages. \[[@pone.0233268.ref006]\] This information is crucial to prognosticate an eye with PXF to prevent disease progression and irreversible damage over long term. This risk also needs to be compared across geographical locations to compare the effect of environment on baseline risks since PXF is known to be highly influenced by climatic and environmental conditions. We had earlier described varied phenotypes and stages of this entity seen in east India and identified increased risk in specific phenotypes of the disease. \[[@pone.0233268.ref005],[@pone.0233268.ref006]\] This study evaluates the disease burden and blindness rates across different PXF stages in patients seen at 4 tertiary centres from two geographically different locations/states with different climatic profiles of India(<https://www.mapsofindia.com/maps/india/annualtemperature.html>).

Methods {#sec010}
=======

Hospital record database at 4 tertiary eye care centres in South (n = 3) and East (n = 1) India of consecutive new and old cases of pseudoexfoliation seen during April 2016 to March 2017 were recruited for a prospective study and screened for baseline variables. The method for ophthalmic work up, stratifying PXF cases into phenotypes or stages and data retrieval from electronic medical record database is detailed elsewhere. \[[@pone.0233268.ref005],[@pone.0233268.ref006]\] In brief, the institutional electronic medical record (EMR) captures all data including demographic, clinical details including Goldmann applanation intraocular pressure (IOP), slit lamp findings, gonioscopy, fundus biomicroscopy findings, medications, surgeries and visual fields data. These data were retrieved from different sections of the patient record in the EMR completed by different perimetrists, optometrists or ophthalmologists and stored in the central EMR server. This study was approved by the institutional review board of each centre including LV Prasad Eye Institute, Mithu tulsi chenrai (MTC) campus Bhubaneswar, KAR campus Hyderabad, KVC campus Vijayawada and GMRV campus Vishakapatnam and the study adhered to the tenets of declaration of Helsinki. Details including demographic information of each patient, slit lamp evaluation with slit lamp photographs, best corrected Snellen visual acuity, clinical pattern of PXF deposits (if described),+90D fundus biomicroscopy and Humphrey visual fields (Carl Zeiss Inc, Dublin, CA, USA, 24--2 SITA standard program), were retrieved from the EMR database at baseline and every visit till final follow up. We also collected details of referrals in the database (which is captured in the clinical EMR database for patients which have been referred to us for tertiary care as opposed to those who presented primarily to us), pattern of deposits, diagnosis and other ocular associations. A uniform definition of PXF and its variants or stages were used to compare data as described elsewhere and below in brief (See below for details of clinical definition or stratification). \[[@pone.0233268.ref005],[@pone.0233268.ref006]\] Patients with incomplete data or indeterminate diagnosis of pseudoexfoliation due to pupillary deposits (for example in uveitis) were excluded. Our earlier study based on a large sample over 2 years found a prevalence rate which was comparable to the disease rates in India and across the globe suggesting that our sample was a close representation of the population sample in our region. \[[@pone.0233268.ref006],[@pone.0233268.ref007]\] Recruitments were done between April 2016 to March 2017 for patients fulfilling inclusion criteria as defined below and a written informed consent from each patient was obtained as per institute protocol.

Management of these cases at each centre including anti-glaucoma medications at baseline and each visit was done as per the clinical faculty's discretion. Decision for surgery in each case and referral to other departments was carried out as per clinical requirements and details of surgery with intraoperative complications (if any) and postoperative course till final follow up were noted for all patients from each location from the central database server. The surgical outcomes at 1 year from each centre were also compared.

Clinical definitions and stratification {#sec011}
=======================================

The definition of Pseudoexfoliation and the clinical variants has been described earlier. \[[@pone.0233268.ref005],[@pone.0233268.ref006]\] Briefly, classical pseudoexfoliation was diagnosed in eyes with evident flaky classical dandruff like exfoliative deposits on the pupil, lens or other ocular structures, open or closed angles on gonioscopy with or without radial pigment over the lens surface on dilated slit lamp evaluation. The three clinical phenotypes based on the clinical features have been described in our earlier study. \[[@pone.0233268.ref005]\] Eyes with clinically evident PXF in any one eye and normal IOP/visual field and optic nerve were classified as pseudoexfoliation syndrome while those with raised IOP \>21mm Hg, normal optic nerve and visual field were diagnosed as PXF with OHT after exclusion of other types of glaucoma. Pseudoexfoliation glaucoma (PXG) was diagnosed in those with glaucomatous optic neuropathy evidenced by cupping, focal notch or retinal nerve fibre layer defects with corresponding reproducible glaucomatous visual field defects (defined as glaucoma hemifield test outside normal limits or pattern standard deviation with probability \<5% with fixation losses\<15% and false positives and false negatives \<30% determining reliability criteria). For those whose fields could not be performed or were unreliable owing to significant cataract/other media opacities, presence of glaucoma was ascertained after cataract removal by evidence of structural glaucomatous damage to the optic nerve.

Unilateral and bilateral eyes and eyes with prior filtering surgeries, lasers, medications or other interventions for controlling IOP were included in the presence of exfoliation material in the eye while absence of clinically evident PXF at any visit (in the contralateral eye of a patient with unilateral PXF) was considered as clinically "normal" eye when associated with a normal IOP and disc/posterior segment. Patients with any other autoimmune or neurodegenerative disorder with corresponding disc changes were excluded. Associated diagnosis noted by clinician in the contralateral eye of unilateral PXF or same eye like lens induced phacomorphic/phacolytic or secondary lens induced angle closure glaucoma associated with the presence of PXF were noted. Co-morbidities in the anterior or posterior segment were recorded and analysed. Medical management was initiated for adequate IOP control in all visits with addition of anti-glaucoma medications while decision for additions/switch or stoppage of medicines (for totally blind asymptomatic eyes) was decided by the clinician at each visit. Follow up management of all eyes with definition of target IOP and surgical success or failure was noted by surgeons at each centre as per standard criteria for every patient.

While blindness and visual impairment definitions vary across studies, measurement of visual field and best corrected visual acuity (BCVA) is not possible for most studies. Since reliable visual field is seldom obtained at the first visit in these PXF eyes with visually significant cataract, the visual criteria henceforth are used for defining disease burden in PXF. So this study herein defines severe visual impairment as measured central visual acuity of 20/200 or less with the best possible correction with/or without a reliable visual field of 20 degrees or less. Eyes with absolutely no measurable amount of useful vision (projection of rays/perception of light) or Snellen BCVA\<20/400 which was reproducible at all visits were termed as absolute blindness. Eyes with fluctuating vision between two consecutive visits were noted separately and not included in the main analysis. The eyes were stratified into 4 groups based on best corrected visual acuity at baseline and final visit as follows- 0-absolute blindness as defined above; 1-\<20/200 and /\>20/400; 2-\<20/100 and \>20/200; 3-\<20/40 an \>20/100 and 4-\>20/40.

Statistics {#sec012}
==========

All data were pooled to a common server for analysis using Stata corp (USA, Version 10) with alpha error set at p\<0.05. Based on our earlier study on \>11,000 cases of PXF, we found a prevalence of 11.5% which was comparable to population based studies in India and across the globe. \[[@pone.0233268.ref005],[@pone.0233268.ref006],[@pone.0233268.ref007]\] The sample size required for the study was calculated to be 155 with a projected prevalence of 11.5%, precision set at 0.05 and 95% confidence intervals. Since we were studying different geographical locations, we chose a minimum sample of 200 from each centre though we included all patients fulfilling inclusion criteria seen and recruited during the study period. Continuous variables are represented as mean (±standard deviation, SD) or median (range) while frequency of features are represented as numbers (n,%). The relative proportion of visual impairment/blindness was analysed separately in each group like PXF stages or unilateral and bilateral PXF while overall proportions among all patients were also collected at baseline. Though there is an increased risk of having pseudoexfoliation in an unaffected eye in unilateral disease, this is highly variable with no clear proven correlation between the two eyes of the same patient. \[[@pone.0233268.ref001]\] Since the diagnosis or severity of PXF in one eye has no clear proven correlation to the risk /condition of the other eye, each eye was taken as a separate unit with no statistical adjustment made for possible correlation between the two eyes of the same patient. The difference in demographic and clinical variables across different centres and different groups was compared using ANOVA statistics. The rates of OHT and PXG and rates of severe visual impairment /blindness across all geographical areas were also compared while proportion of OHT/PXG among cohort in different locations were compared using Chi square. Logistic regression was used to analyse the influence of independent actors like age, IOP, sex, PXF stage, laterality or visual field parameters on risk of blindness.

Results {#sec013}
=======

The mean age of 6284 eyes of 3142 patients seen at all 4 centres during the recruitment period, was 67±8.8 years which included majority of males (F:M = 33%: 67%). Among these, 6.2% were referred patients while the rest presented primarily to the respective centres for the first ophthalmic consultation. This comprised of 1304 unilateral PXF (41.5%) and 1838 (58.5%) bilateral PXF disease. Among 1304 unilateral PXF patients, the contralateral eye was diagnosed as clinically normal at the time of presentation in 1216 patients while 88 were noted by the clinician to have other forms of secondary lens induced glaucoma, [Table 1](#pone.0233268.t001){ref-type="table"}.

10.1371/journal.pone.0233268.t001

###### Demographic and clinical characteristics of eyes with pseudoexfoliation of different stages across 4 tertiary centres and two geographic locations in East and South India.

![](pone.0233268.t001){#pone.0233268.t001g}

                                                                              PXF N = 3024           PXF with OHT N = 144   PXG eyes[\*](#t001fn001){ref-type="table-fn"} N = 1804   Clinically normal eyes N = 1216   P value[^\^^](#t001fn004){ref-type="table-fn"}
  --------------------------------------------------------------------------- ---------------------- ---------------------- -------------------------------------------------------- --------------------------------- ------------------------------------------------
  Age (years)                                                                 67±8.7                 66±8.6                 74±9.2                                                   65±7.9                            0.04
  Unilateral: Bilateral (n, %)                                                961:2063 31.7%:68.2%   21:123 14.5%:85.5%     322:1482 17.8%:82.2%                                     NA                                NA
  Baseline IOP(mm Hg)                                                         15±5.02                18±6.1                 24±11.5                                                  14±4.8                            \<0.001
  SD of IOP over visits (range, mm Hg)                                        7.5(3.1--9.4)          10.3(4.1--12.3)        9.5(6--28.4)[^\$^](#t001fn003){ref-type="table-fn"}      3.6(1.4--6.6)                     0.002
  Number of AGM at presentation (n,%)                                         1--108 (3.5%)          1-97(67.3%)            1-323(17.9%)                                             1-46(37.8%)                       \<0.001
  2-92(3.04%)                                                                 2-16(11.1%)            2-559(30.9%)           2-34(28%)                                                \<0.001                           
  3-38(1.2%)                                                                  3-5(3.4%)              3--376 (20.8%)         3-29(23.8%)                                              \<0.001                           
  4-8(0.2%)                                                                                          4--104 (5.7%)          4-11(9.5%)                                               \<0.001                           
  5--3 (0.09%)                                                                                       5-12(0.6%)                                                                      \<0.001                           
  Time of surgery (months)                                                    33±24.7                31±21.7                32±17.5                                                  34±31.9                           0.09
  Baseline Legal blindness rate[^\#^](#t001fn002){ref-type="table-fn"}(n,%)   992                    38                     632                                                      NA                                
  32.8%                                                                       26.4%                  35%                                                                                                               

\*8 eyes with variable indeterminate vision are not included here

\#-See text for full definition of legal blindness

^\$^ Including some eyes with development of end stage glaucoma(neovascular glaucoma for example)

\^- One Way Anova with maximum differences on posthoc analysis between controls/PXF with PXG; SD-standard deviation; IOP-intraocular pressure; AGM-anti-glaucoma medications; PXF- Pseudoexfoliation; OHT-Ocular hypertension;: PXG-Pseudoexfoliation glaucoma

Stratifying the eyes according to PXF stages, 3024 eyes were noted be having PXF with no evidence of raised IOP or disc damage, 144 OHT eyes with raised IOP and no disc/field damage,1804 PXG with established glaucomatous changes, **[Table 1](#pone.0233268.t001){ref-type="table"}**. Age at presentation was greater for males (74±4.9 years) than females (65±8.8 years) across all geographic regions, p = 0.03. The OHT and PXG eyes presented later than PXF, p = 0.04, **[Table 1](#pone.0233268.t001){ref-type="table"}**. The proportion of OHT or PXG was not significantly different between the two locations of East and South India.

The mean baseline IOP of all eyes was 33±24.7mm Hg with highest IOP seen in PXG eyes, p\<0.001, **[Table 1](#pone.0233268.t001){ref-type="table"}.** Of 1804 PXG eyes, \>50% of eyes required more than 1 medicine with the number of PXG eyes requiring \>3 or 4 medicines being significantly higher than PXF or OHT eyes. The OHT eyes required 1 medicine in 67% while only \<5% eyes required\>2meds for IOP control. It was surprisingly noted that 103 eyes of 1216 normal contralateral eyes of patients with unilateral PXF were receiving medicines prescribed for the eye with PXF at presentation (**See [Table 1](#pone.0233268.t001){ref-type="table"}**). Control of IOP with medicines was achieved by the third visit across all categories with appropriate medical/surgical treatment (mean follow up of 6±3.2 months) with \>50% eyes requiring medicines in PXG eyes and OHT eyes for smoothening IOP fluctuations at follow up visits, **[Table 1](#pone.0233268.t001){ref-type="table"}**. The mean fluctuation of IOP in the study period of 1 year at different visits ranged from 4mm-15mm Hg in PXG eyes while that for OHT and PXF eyes was minimal, **Tables [1](#pone.0233268.t001){ref-type="table"} and [2](#pone.0233268.t002){ref-type="table"}**.

10.1371/journal.pone.0233268.t002

###### Clinical profile of unilateral and bilateral pseudoexfoliation eyes across 4 tertiary centres.

![](pone.0233268.t002){#pone.0233268.t002g}

  Variables                     Unilateral N = 1304   Bilateral N = 3676   P value[\*](#t002fn001){ref-type="table-fn"}
  ----------------------------- --------------------- -------------------- ----------------------------------------------
  Age (years) at presentation   66±8.5                68±9.06              0.058
  Male:Female (%)               64.3:35.6             64.1:35.9            0.4
  IOP baseline(mm Hg)           17±9.1                21±9.2               
  Final IOP (mm Hg)             15±5.6                14±1.9               0.8
  SD of IOP (range, mm Hg)      3.6 (10.8--12.6)      8.06 (11.8--28.4)    0.02
  No of AGM                     1--135 (10.3%)        1-336(9.1%)          0.6
  2--149 (11.4%)                2-427(11.6%)          0.9                  
  3-94(7.2%)                    3-251(6.8%)           0.4                  
  4--20 (1.5%)                  4-74(2.01%)           0.1                  
  5--5 (0.3%)                   5-10(0.2%)            0.8                  

\*- student t test; IOP-intraocular pressure; AGM-anti-glaucoma medications; SD-standard deviation

Comparing unilateral and bilateral PXF eyes, bilateral PXF eyes had significantly higher IOP than unilateral PXF eyes even at 3^rd^ visit and at 1 year with higher SD in the former**, [Table 2](#pone.0233268.t002){ref-type="table"}**. More number of bilateral PXG eyes (52%) required \>2 medicines compared to unilateral PXG eyes (28%) suggesting a severe clinical course at presentation in bilateral PXG eyes. This however did not reflect in overall higher total requirement of anti-glaucoma medications (AGM's) in bilateral PXG suggesting that most bilateral PXG eyes that were blind at presentation may not have been started on medical treatment owing to nil visual prognosis, **Tables [1](#pone.0233268.t001){ref-type="table"} and [2](#pone.0233268.t002){ref-type="table"}**.

A. Visual impairment and blindness rates in PXF stages {#sec014}
------------------------------------------------------

The clinical profile and visual acuity in all stages of PXF as also bilateral and unilateral cases is shown in **Tables [2](#pone.0233268.t002){ref-type="table"}--[4](#pone.0233268.t004){ref-type="table"} and [S1 Table](#pone.0233268.s001){ref-type="supplementary-material"}**. Unilateral cases had \<20% of eyes with visual impairment in all stages at presentation which was significantly lower than bilateral eyes at presentation, **[S1 Table](#pone.0233268.s001){ref-type="supplementary-material"} and [Table 3](#pone.0233268.t003){ref-type="table"}**.

10.1371/journal.pone.0233268.t003

###### Relative proportion of visual impairment or absolute blindness rates in a hospital based multicentric cohort of PXF (Pseudoexfoliation), PXG (Pseudoexfoliative glaucoma), and OHT (PXF with ocular hypertension) at baseline and final visit.

![](pone.0233268.t003){#pone.0233268.t003g}

  Baseline                                                        PXF N = 3024%   OHT N = 144%   PXG N = 1804%   P value   1year                      PXF N = 3024%   OHT N = 144%   PXG N = 1804%   P value
  --------------------------------------------------------------- --------------- -------------- --------------- --------- -------------------------- --------------- -------------- --------------- ---------
  Severe Visual impairment[\*](#t003fn001){ref-type="table-fn"}   (32.8)          (26.4)         \(35\)                    Severe Visual impairment   (25.4)          (20.1)         (44.6)          
  Absolute \*blindness                                            (22.2)          (21.5)         (25.6)                    Absolute blindness         (16.6)          \(16\)         (22.8)          

\*-refer to text for detailed summary of visual impairment/ blindness definitions PXF- Pseudoexfoliation; OHT-Ocular hypertension; PXG-Pseudoexfoliation glaucoma

10.1371/journal.pone.0233268.t004

###### Causes of blindness among all stages of pseudoexfoliation patients seen at two geographical areas.

![](pone.0233268.t004){#pone.0233268.t004g}

  Stage of disease   Cause of blindness/visual impairment
  ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PXF                Un-operated Total/near total Cataract (67%), Posterior segment pathology (17.1%)-Disc pallor, Old Vein occlusion with or without maculopathy Anterior segment pathology (13.2%)- Corneal ulcer, opacities, microbial keratitis, Others (5.7%)-eg. Old retinal detachments or other pathologies like traumatic optic neuropathy
  OHT                Un-operated Total/near total Cataract -74.3% Posterior segment pathology (25.7%)- Vein occlusion, Disc pallor
  PXG                Associated Cataract-66% Posterior segment (23.2%)-Glaucomatous optic neuropathy, Endophthalmitis, Disc pallor, Maculopathy after VR surgery Anterior segment pathology (10.8%) Corneal opacities

PXF-Pseudoexfoliation; OHT-PX PXF with ocular hypertension; PXG-Pseudoexfoliation glaucoma

Comparing stages of glaucoma, PXG eyes had highest rates of visual impairment and absolute blindness at baseline and 1 year, p\<0.001. Eyes with bilateral disease had greater rates of visual impairment (40.6%) compared to unilateral disease (11%) even at presentation, p\<0.001, **[Table 2](#pone.0233268.t002){ref-type="table"} and [S1 Table](#pone.0233268.s001){ref-type="supplementary-material"}, [Fig 1](#pone.0233268.g001){ref-type="fig"}**. In each group, the relative proportion of visually impaired eyes at end of study period at 1 year after appropriate medical/surgical interventions was statistically higher (14.6%) in bilateral PXG eyes compared to bilateral PXF (10.3%) or bilateral OHT (8.8%) or unilateral PXF of any stage, **[S1 Table](#pone.0233268.s001){ref-type="supplementary-material"}**. A worse prognosis in bilateral PXF is suggested by 16% of absolutely blind eyes at baseline and 14% at 1 year after appropriate clinical interventions, **[Fig 1](#pone.0233268.g001){ref-type="fig"}**. This may be due to slightly delayed presentation at baseline in bilateral PXF compared to unilateral PXF, p = 0.058 and a higher proportion of irreversible absolutely blind eyes at presentation, **Tables [2](#pone.0233268.t002){ref-type="table"} and [3](#pone.0233268.t003){ref-type="table"} and [S1 Table](#pone.0233268.s001){ref-type="supplementary-material"}**. This translated to a \>32.9% of overall combined visual impairment and 22.8% absolute blindness in all eyes with pseudoexfoliation in this hospital based cohort at baseline which did not change at 1 year (26.8% and 18.5%, respectively) after standard medical/surgical treatment in all eyes, **Tables [2](#pone.0233268.t002){ref-type="table"} and [3](#pone.0233268.t003){ref-type="table"}**.

![Overall rate of visual impairment and absolute blindness in unilateral and bilateral pseudoexfoliation at baseline showing significantly higher numbers in eyes with bilateral disease (refer to methods for definition of absolute blindness).](pone.0233268.g001){#pone.0233268.g001}

The causes of visual impairment in different stages of PXF at baseline are detailed in **[Table 4](#pone.0233268.t004){ref-type="table"}**. Excluding the reversible causes due to non-operated visually significant cataract which formed the major cause (66--74% across stages), the burden of severe visual impairment and absolute blindness due to irreversible PXG in unilateral and bilateral cases still remained high with significantly higher blindness rates due to PXG in East India compared to South India, **[Fig 2](#pone.0233268.g002){ref-type="fig"}**. Both posterior and anterior segment co-morbidities were associated with PXF related visual impairment in 10--25% of eyes with posterior segment pathologies predominating across PXF stages, [Table 4](#pone.0233268.t004){ref-type="table"}.

![Relative proportion of visual impairment and absolute blindness at baseline and final visits between two geographical locations of East and South India (see text for definitions of visual impairment and absolute blindness, asterix indicates comparison rates between East and South India which were significantly different or p\<0.05).](pone.0233268.g002){#pone.0233268.g002}

Secondary glaucoma in PXF {#sec015}
-------------------------

Pseudoexfoliation is known to be associated with lens induced glaucoma owing to frequent subluxation of the lens and zonular laxity. In eyes with secondary forms of glaucoma (88 eyes with lens induced glaucoma in the contralateral normal eye of unilateral PXF and 8 eyes of unilateral PXF), 55 eyes were on medical treatment while the rest had IOP control after Nd:YAG iridotomy for gonioscopic evidence of angle closure. These secondary glaucoma eyes had a baseline IOP of 20±12mm Hg with final IOP of 15±2.1 mm Hg at 1 year, **[S2 Table](#pone.0233268.s002){ref-type="supplementary-material"}.** The secondary glaucoma eyes had 35% visual impairment and 28% of absolute blindness at presentation which was significantly higher than the blindness rates in other PXF stages, p\<0.001**, [S2 Table](#pone.0233268.s002){ref-type="supplementary-material"} and [Table 1](#pone.0233268.t001){ref-type="table"}**.

The proportion of visual impairment and absolute blindness may be influenced by clinical variables/presentation on the disease severity. To evaluate factors influencing PXF related vision loss at baseline, multivariate analysis was done with independent variables like age, laterality, sex, disease stage, baseline IOP, IOP fluctuations (SD) and baseline visual field parameters like visual field index and pattern standard deviation. Logistic regression showed older age, bilaterality and higher baseline IOP to be significantly associated with higher rates of blindness in PXF eyes, **[S3 Table](#pone.0233268.s003){ref-type="supplementary-material"}**.

B. Surgery outcomes in PXF cases {#sec016}
--------------------------------

We followed up cases which underwent surgery for associated cataract or co-morbidities and evaluated the outcome at the end of the study period from baseline. Of all cases, pupillary dilatation\<5mm was seen in 27.8% eyes while rest had good dilatation with \>6mm dilatation in 2738 eyes (56.7%). **[S4 Table](#pone.0233268.s004){ref-type="supplementary-material"}** details the type of surgeries performed in eyes with PXF with causes for posterior segment associations. Six eyes had intraoperative complications of zonular dialysis. Many eyes could undergo successful cataract or combined cataract and glaucoma surgery with good functional central visual acuity at final visit (visual gain \>2 snellen lines in 86% of eyes undergoing surgery) with no intraoperative complications. While total number of eyes with visual acuity 20/40 or more were significantly lower at final follow up for bilateral cases compared to unilateral PXF, unilateral or bilateral cases undergoing surgery had comparable visual outcomes with no postoperative loss of vision seen in any group. Transient rise of IOP immediately after surgery resolved at 1 week follow up in all cases with none requiring additional medicines/intervention at 1month after surgery. One eye with severe endophthamitis (unknown aetiology) underwent evisceration while 34 eyes with associated lacrimal problems required lacrimal surgery. Postoperative outcomes of trabeculectomy combined with phacoemulsification or small incision cataract surgery were comparable with no statistical difference between final IOP or best corrected visual acuity between the two surgical techniques.

Discussion {#sec017}
==========

This study found relatively high rate of irreversible (and reversible) absolute blindness and visual impiarment in this hospital based cohort spanning two geographical locations. The rates of visual impairment/blindness were significantly higher for bilateral PXG eyes than unilateral PXG or OHT. While\>2/3^rd^ cases of OHT were adequately controlled with 1 medicines, PXG eyes required more than 2 medicines for IOP control. The bilateral cases presented later than unilateral cases, required more medications at presentation and also had greater fluctuations of IOP compared to unilateral cases though the number of AGM was not significantly higher than unilateral cases owing to higher rates of total blindness in the former. Secondary glaucoma is not infrequent in these eyes at presentation where the blindness rates are higher than in PXF eyes with primary PXG. Surgeries for visually significant cataract or uncontrolled IOP in these cases are associated with good visual outcomes. With proper preoperative and intraoperative precautions, complications can be significantly decreased in eyes with secondary glaucoma though the final visual outcome may be poor owing to advanced glaucoma.

Blindness rates due to glaucoma differ significantly across various regions of the globe ranging from 11--30% in different types of primary glaucoma, including POAG and PACG. \[[@pone.0233268.ref012]--[@pone.0233268.ref016]\] Similar studies on PXF report different prevalence rates and rates of PXG associated blindness. \[[@pone.0233268.ref001]--[@pone.0233268.ref003],[@pone.0233268.ref005],[@pone.0233268.ref011],[@pone.0233268.ref012],[@pone.0233268.ref017],[@pone.0233268.ref018]\] Unilateral and bilateral blindness rates in PXF across 7 glaucoma services report a lower prevalence of \<15% and 1.2 respectively which was in contrast to our findings. \[[@pone.0233268.ref017]\] A population based study in southern India reported a rate of 20.5% blindness in PXF with unilateral blindness accounting for 40% though this study did not stratify patients into different stages nor did it reflect the actual burden of reversible versus irreversible blindness.^9^ In another population based study with 25% of bilateral PXF blindness, 89% was due to cataract thereby suggesting that the actual irreversible blindness rates may be lower in that population as compared to our hospital based cohort. \[[@pone.0233268.ref013]\] The very high rates of blindness in this study may reflect a more delayed presentation leading to higher rates of irreversible blindness reflecting the loomingly huge burden of reversible and irreversible blindness/visual impairment rates in PXF compared to other types of glaucoma. The differences in rates of visual impairment across studies arise due to difference in defining criteria for blindness (VA or VF) along with lack of stratification of PXF into different stages as in this study. Our earlier study reported prevalence rates of different stages of PXF at one centre in eastern India with higher prevalence of OHT(20%) and PXG(50%) in bilateral as compared to unilateral PXF(12 and 25% respectively). \[[@pone.0233268.ref005],[@pone.0233268.ref006]\] Since PXF is known to have environmental influences on aetiology and prevalence, we chose two different geographical locations with different profiles; \[[@pone.0233268.ref001],[@pone.0233268.ref002],[@pone.0233268.ref003]\] yet we found minimal differences in proportion of OHT/PXG across the two states suggesting that the risk of stage transitions in PXF were minimally affected by climatic related triggering factors. Baseline difference in PXF prevalence across the globe may possibly only define the baseline genetic predisposition to developing PXF disease and thereby the baseline prevalence rates in different ethnic populations while not particularly affecting the risk for developing glaucoma or OHT. This theory requires concerted large scale efforts at genotype-phenotype correlations with accurate stratification of PXF stages. POAG is recognised as the major cause for blindness in most countries while PACG accounts for majority in select countries with high prevalence of angle closure disease. \[[@pone.0233268.ref011],[@pone.0233268.ref012],[@pone.0233268.ref014],[@pone.0233268.ref015]\] This study identified higher rates of total blindness and visual impairment in bilateral PXG which is important for formulating policies for reducing PXF blindness and spearheading programs for better estimation of PXF burden in the community in addition to common forms of primary glaucoma.

Earlier studies have reported higher rates of PXF associated blindness dependent on age and baseline IOP though they have not analysed the burden of visual impairment across laterality and PXF stages. \[[@pone.0233268.ref001],[@pone.0233268.ref008],[@pone.0233268.ref010],[@pone.0233268.ref018]\] This study observed an aggressive course in bilateral PXG patients with higher IOP in bilateral than unilateral cases. Clinical differences between unilateral and bilateral cases are known in PXF with conversion to the latter over time representing that bilateral disease may be a later clinical form of unilateral PXF. \[[@pone.0233268.ref006],[@pone.0233268.ref008],[@pone.0233268.ref010]\]^,^ The nerve fibre layer in unilateral cases may be thinner compared to normals thereby representing that the manifest form of disease may be considered to be a stage in transition to more aggressive bilateral form over time. \[[@pone.0233268.ref019]\] Yet, the predictor for risk of conversion to bilateral cases or to PXG in any eye with PXF is largely unclear with no correlation to clinical findings. \[[@pone.0233268.ref001],[@pone.0233268.ref005]\] Understanding the genetic landscape in each may suggest if genetic susceptibility also determines an aggressive course in bilateral cases as compared to unilateral cases. Nevertheless, identifying the stage of any PXF eye definitely helps clinicians to predict and prognosticate a possibly faster progression in bilateral PXF as seen in this study to enable timely and aggressive management in these eyes.

We found comparable visual outcomes after surgery in eyes with unilateral and bilateral PXF and found good visual outcomes after surgery in majority of cases. Surgical outcomes in PXF and associated cataract is associated with intraoperative vitreous loss, zonular dialysis, dropped nucleus and postoperative rise in IOP among an array of complications arising due to disease pathophysiology affecting different ocular structures. \[[@pone.0233268.ref020]--[@pone.0233268.ref024]\] While uncomplicated PXF with cataract has comparable surgical outcomes with those of non-PXF eyes, PXF eyes associated with miotic non-dilating pupils, hard nucleus, pre-operative zonular laxity and associated glaucoma pose a significant challenge to surgeons. \[[@pone.0233268.ref007],[@pone.0233268.ref022],[@pone.0233268.ref024]--[@pone.0233268.ref026]\] While most studies focus on phacoemulsification technique in PXF, prospective studies on outcomes with small incision surgery for cataract or combined procedures for glaucoma, most commonly practiced technique in developing countries, versus phaco techniques in these eyes are scarce or absent. \[[@pone.0233268.ref025],[@pone.0233268.ref026]\] Usually, these eyes require sphincterotomy or pupillary dilatation with iris hooks intraoperatively. \[[@pone.0233268.ref023]\] This again causes more trauma as well as heightened inflammatory postoperative inflammation. This study did not find miotic non dilating pupils even in eyes with evident PXF suggesting that most of these eyes can be well managed surgically if adequate pupillary details and lens grade are noted preoperatively. Many eyes underwent lacrimal surgeries as well as retinal procedures mandating careful preoperative evaluation to rule out these associations in these eyes.

The strengths of our study included the large dataset carried out across two geographical locations to explore any effect of environment on disease burden and blindness rates across PXF stages. This was a prospective study thereby reducing inherent flaws of a retrospective design. Further, we used careful and stringent stratification of the stages of PXF to know the risk of blindness in each stage which is crucial and important for accurate prognostication for each eye in glaucoma practice. We also used WHO blindness visual acuity criteria which reflected the true burden of PXF disease in our population which would possibly be used for driving health care planning strategies or avoiding PXF blindness in the two states. Though our earlier hospital based study showed prevalence rates of PXF comparable to population based studies, this was a hospital based prospective study involving 4 tertiary centres; so rates of OHT and PXG or blindness rates in this hospital based cohort may not reflect or may differ from the true population based prevalence rates across the two geographic locations to some extent. This was a multicentric study involving multiple trained surgeons; yet we do not believe this caused any difference in medical or surgical management outcomes in PXF in view of standardised protocols followed at all centres.
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###### Baseline visual acuity and final visual acuity of patients with unilateral or bilateral pseudoexfoliation at different stages (see [methods](#sec010){ref-type="sec"} for detailed description of visual acuity groups 0--4).

(DOCX)

###### 

Click here for additional data file.
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Electronic medical records institute team of LV Prasad Eye Institute which has been instrumental for collecting details and data from across all campuses.

PXF

:   Pseudoexfoliation syndrome

PXG

:   Pseudoexfoliation glaucoma

IOP

:   intraocular pressure

XFM

:   exfoliative material

EMR

:   electronic medical record

TM

:   trabecular meshwork

OHT

:   Ocular hypertension

POAG

:   Primary open angle glaucoma

PACG

:   Primary angle closure glaucoma
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes
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Reviewer \#4: No
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This Research Article designed Prospectively to analyse the disease burden of pseudoexfoliation stages and the data are supportive, Statistical Analysis performed appropriately, All datas underlying the findings are available, The manuscript is written in standard English.

Answer1: We thank the reviewer for the positive comments which encourage us to explore further into pseudoexfoliation which is a baffling disease entity. We are encouraged also to keep up the aulity of our work to meet expectations of the reviewers in the future too.

Reviewer \#2: the only thing I recommend is to add a definition of pseudo exfoliation to the article. the article was written in a very good way, understandable language, clear, and no typo in this article. also the tables were well organized and easy to understand by the reader.

Answer 2: We than the reviewer for this suggestion which has been added, as suggested.

Reviewer \#3: I read with interest the article entitled .: \"Visual impairment in pseudoexfoliation from four tertiary centers in India\" by Aparna Rao al., Regarding pseudoexfoliation (PXF) disease stages from East and South India. This research concerns a large number of individuals (over 6.ooo patients). I found it very difficult to read this article because I didn\'t like it. From an epidemiological point of view this syndrome first discovered in the Scandinavian countries is now considered ubiquitous. The authors state that it is not known why this glaucoma comes. Actually, the furfuraceous material that can be found in any organ indicates a serious alteration of the metabolism of the tissues involved. High pressure glaucoma consists from a molecular point of view in pro-apoptotic signals that reach the head of the optic nerve and induce the 1death of ganglion cells. Therefore, trabecular meshwork is the first tissue to be involved (see Saccà et al. From DNA damage to functional changes of the trabecular meshwork in aging and glaucoma. Aging Res Rev. 2016; 29: 26-41) and trabecular dandruff there suggests that this structure is seriously damaged and therefore unable to fulfill its barrier functions (Saccà et al. The Outflow Pathway: A Tissue With Morphological and Functional Unity. J Cell Physiol. 2016; 231: 1876-93), hence the increase in intraocular pressure and glaucoma. Even the diagnosis of pseudoexfoliative glaucoma may not be so simple, indeed, according to the only macroscopic presence of the dandruff is uncertain. This syndrome acts like multiple sclerosis. Depending on the affected tissue, the nosological entity of the disease manifests itself: if the iris is affected, iris atrophic changes occur if the lens is affected, the cataract occurs, if the zonula is affected, lens dislocation occurs, if the trabecular meshwork is affected, have glaucoma.

Answer 3: We agree with the reviewer's pertinent views regarding possible mechanisms of tissues getting affected with the exfoliative material. The disease is ubiquitous as pointed out however this occurs with varied prevalance rates across the globe. This topic of glaucoma in PXF is indeed a complex issue which has baffled many scientist and has eluded a clear description of events leading to glaucoma. Yet, it is known that presence of exfoliative material by itself does not mean functional disturbances which is reported in studies showing no correlation of extent of exfoliative deposits in eye with presence of glaucoma (Cobb J et al- Br J Ophthalmol 2004; 88:1002-1003) If material causes mechanical blockage of TM pores with the deposits in all eyes, glaucoma would be seen in all eyes with PXF which is rarely seen in clinical practice. While it is known that these may cause local functional disturbances in the tissues including the TM, the mechanism by which that happens and what triggers the disturbance in some eyes at specific time points only is unknown. This is exactly the reason why all eyes with PXF do not end up with glaucoma even in the same patient with bilateral disease. The molecular events triggering the functional tissue damage is also largely unclear which is discussed in the review article (reference 1). Similar perplexing issues of the disease are discussed in the Journal of glaucoma supplement 1, Volume 27, 2018 discussing several perplexing issues on this disease .Our own lab is working at unraveling the disturbances in eyes with PXF and those without PXG at a molecular level. We also are aware of TM functional damage and cell death in glaucoma in general but would like to clarify that it is not only apoptosis that causes cell death in the human TM in glaucoma. My PhD thesis study evaluating cellular mechanisms of cell death in TM (which largely involved insights from Dr Sacca's work an articles) found specific molecular events being triggered at specific severity of tissue damage which is not restricted to apoptotic signals only and rather involved a down-regulation of apoptotic molecules contrary to traditional wisdom (paper under review). We are also studying how TM in PXG eyes are affected and are working on an in vitro-model of the same. While several others are also working on the questions the reviewer has suggested and alluded above, we still believe that the glaucoma pathogenesis in PXF remains a mystery. This is the reason why we clinicians cannot predict which eyes are at risk of developing glaucoma and also fall short in predicting when the onset of glaucoma/or tissue damage can occur in any eye. We would be delighted to share our preliminary results with the reviewer when experiments complete regarding the above points of TM damage in PXF and we would be happy to get further insights from the reviewer on this topic.

Reviewer \#4: Although in general the manuscript is presented in an intelligible fashion, there are some errors in the use and structure of the English language which make it hard to follow at some points. Proofreading and better use of the english language should be highly considered. Some of them are highlighted in the comments.

methods in abstract, Line 37: clinical \"and\" demographic details instead of clinical, demographic should be used

Line 87: missing the word \"primary\" before angle closure glaucoma (PACG)

Line 88: focus instead of focuses should be used

Line 111: \"electronic media record database\": do the authors mean media or medical?

Line 111-116: sentence is hard to follow. medications is written twice.

Line 123: Does \"pattern of deposits, diagnosis, ocular associations and number of medications at baseline\" refer to data collected from referrals outside? It is not clear to the reader.

Line 137: \"open or closed angles on gonioscopy, radial\" missing the word \"and\" before radial

Line 143: Missing the word pseudoexfoliation before glaucoma

Line 161: \"anti-glaucoma educations\". educations should be replaced by the appropriate word

Line 162: \"(for totally bind asymptomatic eyes)\"bind should be replaced by the appropriate word

Line 184: \"proportions among al patients\"al should be replaced by the appropriate word

Line 185: \"Since the diagnosis or severity of PXF in one eye has no proven correlation to the risk /condition of the other eye\", However the authors should consider that there is a variable but increased probability of developing Pseudoexfoliation in the unaffected eye

Line 191: locations instead of location

Line 198: add \"the\" before rest

Line 210\" authors should include if this finding was statistically significant

Line 212: add \"being\" before significantly

Line 217: missing word after medical/surgical

Line 220: \"were\" should be replaced with \"was\"

Line 226: abbreviation AGM was not explained

Line 256: The authors mention that anterior and posterior segment pathologies were noted and analyzed. However it is not clear If they stratified for these pathologies as they could significantly impact visual acuity apart from the glaucomatous changes.

Line 366: removed one of the two \"with\"

Line 508:SD was not included in the list with abbreviations

Figure 1 does not show up properly. Please review.

Figure 2 seems blurry.

Answer: We than the reviewer for such an exhaustive review and correction at appropriate places. The text has been edited for grammar and typos. All detailed corrections given above have been incorporated, as suggested. The resolution of figures has also been improved, as suggested.
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#4: Yes
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#4: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This Research Article designed Prospectively to analyse the disease burden of pseudoexfoliation stages and the data are supportive, Statistical Analysis performed appropriately, All datas underlying the findings are available, The manuscript is written in standard English.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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